Comparative Pharmacology
Head-to-head clinical analysis: METHADOSE versus OXYCODONE 2 5 APAP 500.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHADOSE versus OXYCODONE 2 5 APAP 500.
METHADOSE vs OXYCODONE 2.5/APAP 500
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methadone is a mu-opioid receptor agonist; it also acts as an NMDA receptor antagonist and inhibits serotonin and norepinephrine reuptake, contributing to its analgesic and detoxification effects. It has a long half-life and reduces opioid craving and withdrawal symptoms.
Oxycodone is a mu-opioid receptor agonist that inhibits ascending pain pathways and alters pain perception. Acetaminophen inhibits cyclooxygenase (COX) enzymes, reducing prostaglandin synthesis.
Oral: 20-40 mg once daily, titrated to effect; for opioid dependence, typical maintenance 80-120 mg/day. IV: 2.5-10 mg every 8-12 hours.
1-2 tablets (oxycodone 2.5-5 mg/APAP 500-1000 mg) orally every 4-6 hours as needed for pain; maximum APAP 4000 mg/day (consider lower APAP limit per institutional guidelines).
None Documented
None Documented
Terminal elimination half-life range: 8–59 hours (mean ~20–35 hours). In chronic use, half-life may increase due to accumulation. Context: The long half-life supports once-daily dosing for opioid dependence but requires careful titration to avoid accumulation.
Oxycodone: 3.5-5.5 hours in healthy adults; steady state reached within 24 hours. Acetaminophen: 2-3 hours; prolonged in hepatic impairment.
Primarily renal (approximately 80%) as inactive metabolites, with about 20% eliminated via feces. Less than 10% excreted unchanged.
Oxycodone: primarily renal (87% as metabolites, 10% unchanged). Acetaminophen: primarily renal (90-100% as glucuronide and sulfate conjugates, 2-5% unchanged). Fecal elimination <10%
Category C
Category D/X
Opioid Agonist
Opioid Agonist